Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group.
Jennings MT, Sposto R, Boyett JM, Vezina LG, Holmes E, Berger MS, Bruggers CS, Bruner JM, Chan KW, Dusenbery KE, Ettinger LJ, Fitz CR, Lafond D, Mandelbaum DE, Massey V, McGuire W, McNeely L, Moulton T, Pollack IF, Shen V. Jennings MT, et al. Among authors: shen v. J Clin Oncol. 2002 Aug 15;20(16):3431-7. doi: 10.1200/JCO.2002.04.109. J Clin Oncol. 2002. PMID: 12177103 Clinical Trial.
High Incidence of Veno-Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (CCG-99702).
Nazemi KJ, Shen V, Finlay JL, Boyett J, Kocak M, Lafond D, Gardner SL, Packer RJ, Nicholson HS. Nazemi KJ, et al. Among authors: shen v. Pediatr Blood Cancer. 2016 Sep;63(9):1563-70. doi: 10.1002/pbc.26074. Epub 2016 May 20. Pediatr Blood Cancer. 2016. PMID: 27203542 Free PMC article.
Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience.
Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Sposto R, Finlay JL. Zaky W, et al. Among authors: shen v. Pediatr Blood Cancer. 2014 Jan;61(1):95-101. doi: 10.1002/pbc.24648. Epub 2013 Aug 11. Pediatr Blood Cancer. 2014. PMID: 23934933 Clinical Trial.
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
Bracho F, Krailo MD, Shen V, Bergeron S, Davenport V, Liu-Mares W, Blazar BR, Panoskaltsis-Mortari A, van de Ven C, Secola R, Ames MM, Reid JM, Reaman GH, Cairo MS. Bracho F, et al. Among authors: shen v. Clin Cancer Res. 2001 Jan;7(1):58-67. Clin Cancer Res. 2001. PMID: 11205919 Clinical Trial.
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Jeha S, et al. Among authors: shen v. J Clin Oncol. 2006 Apr 20;24(12):1917-23. doi: 10.1200/JCO.2005.03.8554. J Clin Oncol. 2006. PMID: 16622268 Clinical Trial.
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
Cairo MS, Shen V, Krailo MD, Bauer M, Miser JS, Sato JK, Blatt J, Blazar BR, Frierdich S, Liu-Mares W, Reaman GH. Cairo MS, et al. Among authors: shen v. J Pediatr Hematol Oncol. 2001 Jan;23(1):30-8. doi: 10.1097/00043426-200101000-00008. J Pediatr Hematol Oncol. 2001. PMID: 11196267 Clinical Trial.
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS, Davenport V, Bessmertny O, Goldman SC, Berg SL, Kreissman SG, Laver J, Shen V, Secola R, van de Ven C, Reaman GH. Cairo MS, et al. Among authors: shen v. Br J Haematol. 2005 Jan;128(1):49-58. doi: 10.1111/j.1365-2141.2004.05281.x. Br J Haematol. 2005. PMID: 15606549 Free article. Clinical Trial.
Feasibility study of IL-11 and granulocyte colony-stimulating factor after myelosuppressive chemotherapy to mobilize peripheral blood stem cells from heavily pretreated patients.
Goldman SC, Bracho F, Davenport V, Slack R, Areman E, Shen V, Lenarsky C, Weinthal J, Hughes R, Cairo MS. Goldman SC, et al. Among authors: shen v. J Pediatr Hematol Oncol. 2001 Jun-Jul;23(5):300-5. doi: 10.1097/00043426-200106000-00013. J Pediatr Hematol Oncol. 2001. PMID: 11464987 Clinical Trial.
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada H, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK; Children’s Oncology Group. Baker DL, et al. N Engl J Med. 2010 Sep 30;363(14):1313-23. doi: 10.1056/NEJMoa1001527. N Engl J Med. 2010. PMID: 20879880 Free PMC article. Clinical Trial.
247 results